Business Wire

Verlingue Strengthens Its Position in Europe by Gaining a Foothold in Italy With the Acquisition From ISA of a Majority Stake in INSER

12.7.2023 11:33:00 EEST | Business Wire | Press release

Share

Verlingue announces the acquisition of a majority stake in the insurance broker INSER, in line with its Verlingue 2024 strategic plan to create a major European, family-owned, independent insurance broker. This move to acquire a stake in the Italian market consolidates this ambition:

  • Verlingue has chosen Italy as its fifth country of operations after France, the UK, Switzerland and Portugal.
  • INSER is Verlingue's 7th international acquisition in 7 years
  • Verlingue has become a majority shareholder in the Italian broker INSER, one of Italy's leading independent brokers
  • The long-standing shareholder, ISA, remains a minority shareholder in INSER to continue to support its growth in Italy
  • 160 INSER employees are joining Verlingue, whose international turnover now accounts for 35% of its total turnover.

Founded in 1979 in Trento, INSER is one of the leading independent players in the Italian insurance brokerage market. It focuses on corporate risks and public procurement. The Italian broker, which has expanded through targeted organic growth and a strategic acquisitions programme, employs nearly 160 staff in 8 offices in northern Italy (Trento, Parma, Brescia, Milan, Bergamo, Vicenza, Udine) and central Italy (Rieti).

With Italy, Verlingue is entering an important strategic market by making its seventh acquisition outside France in seven years, following on from its acquisitions in Switzerland (2016, 2017 and 2019), the UK (2018) and Portugal (2020, 2022).

With this new acquisition, the Adelaïde Group continues to execute its 2024 strategic plan with the ambition of becoming a major European, family-owned, independent insurance broker, serving increasingly international customers. Verlingue's ambition in Italy is to become a benchmark broker in the market for SMEs, mid-caps, large companies and public authorities. Verlingue will be able to rely on the current management team.

Under the terms of the partnership, Verlingue will become INSER's majority shareholder, while its long-standing shareholder, ISA, will retain a minority stake and continue to support its growth in Italy.

Giorgio Franceschi, Deputy Chairman of ISA, said: “We are delighted with this acquisition. We have found a solid and credible international partner in the family-owned Verlingue group, which will now contribute to a new phase in the development of INSER, a long-standing and important subsidiary of ISA, which we have supported in its growth and in which we will continue to be present. The partnership between Verlingue and ISA offers a great opportunity to create value for customers, employees and the region as a whole.”

Regarding the partnership, Pierpaolo Ruggeri, CEO of Inser Spa, said: “Verlingue's European project is exciting and Italy is a strategic country. This partnership will enable us to strengthen our development trajectory, both through organic growth and targeted acquisitions, in order to consolidate our positioning and offer a high-quality service to our customers.”

Benjamin Verlingue, Deputy CEO of the Adelaïde Group: “I am delighted that Adelaïde is setting up operations in Italy, Europe's fourth-largest insurance market. This opens up many positive prospects for our customers, who are becoming increasingly international.

In an industry that is consolidating, being a family-run broker with an ambitious, long-term vision means that we can offer an appealing plan to the teams who decide to join us. I'm very pleased that Inser and ISA made this choice.”

Anne-Jacques de Dinechin, Chief Executive Officer of Verlingue, said: “Our international success is based on strong local management teams in each country. With the acquisition of Inser, we are bringing on board a team of committed experts who will play a full part in our goal to become a major player in Europe.”

About Verlingue

An insurance broker specialising in business protection, Verlingue is a subsidiary of the Adelaïde Group.

Working alongside entrepreneurs, Verlingue’s goal is to harness corporate risk management and employee protection to drive its customers’ value creation and performance.

With offices in France, Portugal, Switzerland, Great Britain and Italy, and through partners in over 100 countries, Verlingue works with its customers over the long term and at all times to better understand and plan ahead for new risks in order to develop simple yet effective solutions to protect their business (corporate risk) and staff (supplementary social protection schemes and pensions).

1,350 employees, 550 of whom are based outside France
€2,350m in premiums negotiated on behalf of its customers
Operating out of 5 countries in Europe
LinkedIn/www.verlingue.fr

About Inser

Leading insurance broker providing protection for companies and public bodies. With over 40 years of experience in Italy, INSER is able to meet the specific needs of each of its customers with a team of employees capable of developing personalised solutions with the utmost care and professionalism. With 8 offices in Italy, INSER has a strong regional presence, ensuring that it is close to its customers and therefore able to generate value.

160 employees
€130m in premiums negotiated on behalf of its customers
8 locations
LinkedIn/www.inserspa.eu

About ISA

Istituto Atesino di Sviluppo Spa (ISA) is a holding company that has been operating in Trentino-Alto Adige and neighbouring regions for over 90 years. ISA's aim is to acquire stakes, mainly minority ones, by investing in diversified initiatives with the role of a patient long-term partner, with a view to creating value. Investments are selected with the utmost care and rigour, with a view to creating a sustainable development path that is attentive to social and economic growth. Through an effective network of contacts, ISA brings together private capital and financial institutions, generating opportunities for investment, growth and development.

https://isa.tn.it/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact
Adelaïde Group – Thomas Barbelet – thomas.barbelet@verlingue.fr – +33(0)6 72 75 49 14
Epoka Agency – Lucie Fortin – lfortin@epoka.fr – +33(0)6 19 68 70 18

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye